"HIV Seropositivity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).
| Descriptor ID |
D006679
|
| MeSH Number(s) |
C02.782.815.616.400.500 C02.800.801.400.500 C20.673.480.500
|
| Concept/Terms |
HIV Seropositivity- HIV Seropositivity
- HIV Seropositivities
- Seropositivities, HIV
- Seropositivity, HIV
- AIDS Seropositivity
- AIDS Seropositivities
- Seropositivities, AIDS
- Seropositivity, AIDS
- Anti-HIV Positivity
- Anti HIV Positivity
- Anti-HIV Positivities
- Positivities, Anti-HIV
- Positivity, Anti-HIV
- HTLV-III Seropositivity
- HTLV III Seropositivity
- HTLV-III Seropositivities
- Seropositivities, HTLV-III
- Seropositivity, HTLV-III
- HIV Seroconversion
- HIV Seroconversions
- Seroconversion, HIV
- Seroconversions, HIV
- HTLV-III Seroconversion
- HTLV III Seroconversion
- HTLV-III Seroconversions
- Seroconversion, HTLV-III
- Seroconversions, HTLV-III
- AIDS Seroconversion
- AIDS Seroconversions
- Seroconversion, AIDS
- Seroconversions, AIDS
- HIV Antibody Positivity
- Antibody Positivities, HIV
- Antibody Positivity, HIV
- HIV Antibody Positivities
- Positivities, HIV Antibody
- Positivity, HIV Antibody
|
Below are MeSH descriptors whose meaning is more general than "HIV Seropositivity".
Below are MeSH descriptors whose meaning is more specific than "HIV Seropositivity".
This graph shows the total number of publications written about "HIV Seropositivity" by people in this website by year, and whether "HIV Seropositivity" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 26 | 14 | 40 |
| 1996 | 22 | 17 | 39 |
| 1997 | 20 | 23 | 43 |
| 1998 | 23 | 8 | 31 |
| 1999 | 22 | 10 | 32 |
| 2000 | 15 | 9 | 24 |
| 2001 | 19 | 14 | 33 |
| 2002 | 20 | 12 | 32 |
| 2003 | 30 | 16 | 46 |
| 2004 | 24 | 20 | 44 |
| 2005 | 27 | 22 | 49 |
| 2006 | 38 | 8 | 46 |
| 2007 | 24 | 15 | 39 |
| 2008 | 26 | 15 | 41 |
| 2009 | 23 | 13 | 36 |
| 2010 | 23 | 14 | 37 |
| 2011 | 36 | 20 | 56 |
| 2012 | 40 | 28 | 68 |
| 2013 | 38 | 17 | 55 |
| 2014 | 40 | 21 | 61 |
| 2015 | 20 | 11 | 31 |
| 2016 | 26 | 20 | 46 |
| 2017 | 16 | 14 | 30 |
| 2018 | 18 | 18 | 36 |
| 2019 | 17 | 11 | 28 |
| 2020 | 14 | 9 | 23 |
| 2021 | 13 | 6 | 19 |
| 2022 | 25 | 0 | 25 |
| 2023 | 20 | 0 | 20 |
| 2024 | 8 | 7 | 15 |
Below are the most recent publications written about "HIV Seropositivity" by people in Profiles.
-
Assessing a Couples-Based, Digital HIV Serostatus-Neutral Intervention (Para Ti, Para Mí, Para Nosotros) for Adult Cisgender Sexual Minority Male Couples in Lima, Peru: Protocol for a 6-Month Pilot Randomized Controlled Trial. JMIR Res Protoc. 2024 Oct 10; 13:e63106.
-
Prompt Initiation of Maternal Antiretroviral Therapy After HIV Seroconversion in Pregnancy Effectively Prevents Vertical Transmission and Other Adverse Infant Outcomes. Pediatr Infect Dis J. 2025 Jan 01; 44(1):40-43.
-
Relationships Between Hepatic Steatosis and Frailty Differ by HIV Serostatus. J Acquir Immune Defic Syndr. 2024 Oct 01; 97(2):165-171.
-
Safe Injection Self-Efficacy is Associated with HCV and HIV Seropositivity Among People Who Inject Drugs in the San Diego-Tijuana Border Region. AIDS Behav. 2024 Nov; 28(11):3629-3642.
-
"We chose PrEP because I wanted to be sure that this child my wife was going to conceive was indeed mine." Factors influencing the choice of safer conception methods and experiences with its use: a qualitative study among HIV sero-discordant couples in Zimbabwe. BMC Public Health. 2024 Jul 19; 24(1):1936.
-
"First was to sit down and bring our minds together". A qualitative study on safer conception decision-making among HIV sero-different couples in Zimbabwe. Sex Reprod Health Matters. 2024 Dec; 32(1):2366587.
-
Longitudinal Analysis of Overlapping Psychosocial Factors Predicting Incident Hospitalization Among Mixed HIV Serostatus Men who have Sex with Men in the Multicenter AIDS Cohort Study. AIDS Behav. 2024 Sep; 28(9):1-12.
-
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS. JCI Insight. 2024 Apr 08; 9(7).
-
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study. Lancet HIV. 2024 Apr; 11(4):e222-e232.
-
Kinetic coevolutionary models predict the temporal emergence of HIV-1 resistance mutations under drug selection pressure. Proc Natl Acad Sci U S A. 2024 Apr 09; 121(15):e2316662121.